EP-1069 ASSOCIATION BETWEEN LIFE PROGNOSIS AND PRETREATMENT LIVER FUNCTION OF PROTON BEAM THERAPY FOR THE PATIENTS WITH HCC

median OS was 35 months (95% CI: 29,3-40,6). There were significant differents in PFS between patients who underwent surgery of metastases versus non-operated (p = 0.001) by Log-Rank test. Conclusions: Neoadyuvant RCT is feasible approach for metastatic rectal cancer, offering good outcomes in-field tumor control, survival and low toxicity profile. Further investigation is warranted in order to define their integration into the multimodality treatment in this patient population.